Rezafungin, a New Second-Generation Echinocandin
Rezafungin is a novel systemic antifungal agent of the echinocandin class, which was approved by the US Food and Drug Administration (FDA) in March 2023 for the treatment of candidemia and invasive candidiasis in adults with limited treatment options.